Deka Bank Deutsche Girozentrale Geron Corp Transaction History

Deka Bank Deutsche Girozentrale

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 24, 2023	BUY	$2.14 - $3.4 $256,800 - $408,000	120,000 New	120,000 $251,000
Q4 2021 Feb 02, 2022	SELL	$1.22 - $1.72 $122,000 - $172,000	-100,000 Closed	0 $0
Q4 2020 Mar 12, 2021	BUY	$1.55 - $2.05 $155,000 - $204,999	100,000 New	100,000 $153,000
Q3 2019 Nov 14, 2019	SELL	$1.15 - $1.59 $47,149 - $65,190	-41,000 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$1.37 - $2.02 $21,920 - $32,320	16,000 Added 64.0%	41,000 $62,000
Q1 2019 May 10, 2019	BUY	$1.01 - $1.83 $4,545 - $8,235	4,500 Added 21.95%	25,000 $135,000
Q4 2018 Feb 12, 2019	SELL	$0.98 - $1.85 $4,410 - $8,325	-4,500 Reduced 18.0%	20,500 $20,000
Q1 2018 May 03, 2018	BUY	$1.81 - $5.98 $45,250 - $149,500	25,000 New	25,000 $106,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.54B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.